Related Experiment Video
Updated: Apr 20, 2026
11:17
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
Published on: February 27, 2026
573
Superior vena caval resection in lung cancer
Dong-Seok D Lee1, Raja M Flores1
1Department of Thoracic Surgery, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1023, New York, NY 10029, USA.
Thoracic Surgery Clinics
|December 3, 2014
Summary
Lung cancer involving the superior vena cava (SVC) is rare and challenging to manage. Early N2 disease detection and induction therapy are crucial for favorable long-term outcomes with careful surgical selection.
Area of Science:
- Oncology
- Thoracic Surgery
- Pulmonary Medicine
Background:
- Lung cancer involving the superior vena cava (SVC) presents a rare but significant management challenge.
- Accurate staging, particularly identifying N2 disease, is critical for treatment planning.
Purpose of the Study:
- To highlight the challenges and optimal management strategies for lung cancer with SVC involvement.
- To emphasize the importance of induction therapy and careful patient selection for surgery.
Main Methods:
- Review of clinical data and treatment outcomes for lung cancer patients with SVC involvement.
- Analysis of the impact of induction therapy on resectability and long-term survival.
- Evaluation of criteria for surgical candidacy in this patient cohort.
Main Results:
- Lung cancer with SVC involvement requires meticulous diagnostic evaluation.
- Induction therapy can downstage N2 disease, improving surgical candidacy.
- Carefully selected patients can achieve favorable long-term outcomes following surgical resection.
Conclusions:
- Lung cancer with SVC involvement necessitates a multidisciplinary approach.
- Early recognition of N2 disease and neoadjuvant treatment are key.
- Specialized centers are essential for optimal surgical selection and management.
